Physician profile
Mark Pomerantz
NPI 1184700551
$7,903.15
in general payments reported to CMS, 2019-2025
40 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $605 · 2021: $800 · 2022: $997 · 2023: $1,158 · 2024: $1,453 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,378 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,377.87 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $815.46 | 2019-2025 | Jardiance |
| Amgen INC. | $776.82 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $708.63 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $585.63 | 2019-2025 | |
| Pfizer INC. | $553.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $536.92 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $519.31 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $306.64 | 2022-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $303.86 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $228.54 | 2023-2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $214.97 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $206.54 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.07 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $187.01 | 2021-2025 | Onpattro, Amvuttra |
| Regeneron Healthcare Solutions, INC. | $174.02 | 2019-2023 | Evkeeza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $162.77 | 2024-2025 | |
| Boston Scientific Corporation | $143.08 | 2019-2024 | Latitude Communicator Power Supply |
| Arbor Pharmaceuticals, INC. | $143.04 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $116.44 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $109.28 | 2020-2025 | Nexletol |
| Akcea Therapeutics, INC. | $95.88 | 2019-2021 | |
| Bridgebio Pharma, INC. | $82.81 | 2025 | Attruby |
| Genzyme Corporation | $76.10 | 2022-2023 | |
| Celgene Corporation | $74.82 | 2024-2025 | Camzyos |
| Lundbeck LLC | $62.35 | 2020-2021 | |
| Baxter Healthcare | $53.62 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $52.99 | 2020-2022 | |
| Lilly USA, LLC | $52.43 | 2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $50.22 | 2025 | Arexvy, Shingrix |
| Philips North America LLC | $49.44 | 2024-2025 | Mcot, (Ck7) Extended Holter |
| Azurity Pharmaceuticals, INC. | $43.76 | 2025 | Edarbi |
| Kiniksa Pharmaceuticals, LTD. | $42.07 | 2021-2023 | Arcalyst |
| Gilead Sciences, INC. | $37.28 | 2019 | |
| G Medical Diagnostic Services, INC. | $35.53 | 2019-2022 | |
| Abbott Laboratories | $24.44 | 2024 | Jot Dx |
| Medicomp INC | $21.67 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.72 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $16.46 | 2024 | Arcalyst |
| Ge Healthcare | $14.74 | 2025 | |
| Sanofi Pasteur INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pomerantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.